Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06579183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pilot Trial for Health Products on Mood and Sleep Quality

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Start date changed from estimate of Sep 2026 to Sep 22, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Study site revised
    • Publications: details revised at 4 of 4 entries
  2. Minor Re-verified, no change to tracked fieldsv7
  3. Notable Start date: Jun 2025 to Sep 2026v6 Show 10 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Dec 2027 to Sep 2027
    • Study completion date: Dec 2028 to Sep 2028
    • Interventions: Extra Strength Vita Calm (ES/VC) (Dietary Supplement), Extra Strength VitaJoy (ES/VJ) (Dietary Supplement), Placebo (Dietary Supplement) to Placebo (Dietary Supplement), Vita Calm Deep Sleep Formula (VCDSF) (Dietary Supplement), Vita Calm Mood Booster Formula (VCMBF) (Dietary…
    • Eligibility criteria expanded, about 112 words
    • Secondary endpoints: 5 to 7
    • Study description expanded, about 316 words
    • Site details revised
    • Collaborators expanded, about 6 words
    • Study title revised
  4. Notable Primary completion date: Dec 2026 to Dec 2027v5 Show 6 more changesShow less
    • Study completion date: Dec 2027 to Dec 2028
    • Start date: May 2025 to Jun 2025
    • Eligibility criteria expanded, about 120 words
    • Secondary endpoints: 3 to 5
    • Study description expanded, about 172 words
    • Study title revised
  5. Notable Start date: Dec 2024 to May 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Re-verified, no change to tracked fieldsv3
  2. Notable Primary endpoint revised
    • Secondary endpoints revised (3)
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pilot, single-site clinical trial that will follow a randomized, double-blinded, parallel-group, placebo-controlled design. A total of 60 participants aged 18-65 will be recruited for a 12-week intervention, followed by a 4-week observational phase and a post-intervention visit at week 16. Participants will attend five scheduled visits at 4-week intervals (baseline, weeks 4, 8, 12, and 16) at the Specialist Clinical Centre for Teaching and Research, School of Chinese Medicine, the University of Hong Kong (HKUSCM). At each visit, assessments will include psychological attributes and sleep quality. Participants will be randomly allocated to one of 2 groups (n=30 per group): the intervention group, which will receive VCMBF and VCDSF, and the control group, which will receive a placebo matched for appearance, smell, and taste. Written informed consent will be obtained from each participant prior to the commencement of the study. The primary outcome will be overall mental health, accessed by the Depression, Anxiety and Stress Scale - 21 items (DASS-21). Secondary outcomes will include anxiety status, measured by the Chinese version of the Beck Anxiety Inventory (BAI-C); depression status, measured by the Chinese version of the Beck Depression Inventory-II (C-BDI-II); stress levels, measured by the Perceived Stress Scale (PSS); psychological well-being, measured by the General Health Questionnaire-28 (GHQ-28); quality of life, assessed using the WHOQOL-BREF (Hong Kong version); and sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI), the Mi wristband as an objective measure, and the Consensus Sleep Diary (CSD) for cross-validation. Tongue and pulse characteristics will also be recorded for qualitative analysis. Safety profiles of VCMBF and VCDSF will be evaluated throughout the study. Assessments will occur every four weeks until week 16, with tongue and pulse characteristics recorded at baseline, week 12, and week 16. A generalized linear mixed-effect model will be applied to compare outcomes over time in the 2 groups.
Trial Details
NCT Number NCT06579183
Lead Sponsor The University of Hong Kong
Collaborators: Vita Green Health Products Co. Ltd
Conditions
(from sponsor)
Sleep Disturbance, Emotional Disturbance
Related terms Affective Symptoms, Parasomnias
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov